Contact


A global team. One mission: Unlocking intracellular targets

Our sites

Eximmium was founded in 2021, with teams based in Germany, Singapore, and China.

By combining the scientific innovation of our Munich site with strong development and clinical execution capabilities in Singapore and China, Eximmium operates as a fully integrated, globally positioned platform. This structure enables rapid discovery, validation, and advancement of breakthrough antibody therapeutics with high translational potential.

Our Vision

We strive to outsmart cancer and give patients a life worth living.

Meet

the Management

Science paired with clinical expertise – we believe that innovative thinking and courage make the change to a healthier future.

Interested in getting to know more? Let’s talk!

Contact us

Victor Li Lietao

Linkedin

Founder & CEO 

View Bio

Reinhard Zeidler

Linkedin

Scientific Founder

View Bio

Zhou Tielin

Linkedin

Head of Operations (Singapore)

View Bio

Kathrin Gärtner

Linkedin

Head of Operations (Munich)

View Bio

Let´s get in touch

Interested in working with us or learning more about our antibodies and targets? We are looking forward to hearing from you.

Eximmium

Contact Us

Singapore

Munich

Close

Victor Li Lietao

Dr. Li builds biotech ventures to advance first-in-class immunotherapies for unmet medical needs. He is the full-time CEO of Eximmium. As the founding CEO of multiple ventures, he led the development of novel therapies, including adjuvanted vaccines and TCR/CAR-T cell therapies targeting viral infections and related cancers into clinical stages. Several lead assets have since advanced to Phases II and III trials. With over 30 years in biopharma and clinical medicine, Dr. Li has held strategic product roles in global pharma and consulting. 

Close

Reinhard Zeidler

Prof. Zeidler is a global expert in extracellular vesicle (EV) and antibody research at the LMU University Hospital and Helmholtz Munich. His pioneering work using EVs to identify cancer-specific targets and develop first-in-class antibodies led to the creation of the EximABTM technology. Three of these therapeutic antibodies that were generated in his lab are currently in clinical development, including a first-in-class Fab-fragment licensed to ITM Isotype Technologies SE for the treatment of glioblastoma. As the inventor behind Eximmium’s core technology, he holds over 15 patents and has authored more than 100 peer-reviewed publications. 

Close

Tielin Zhou

Dr. Zhou brings 23 years of experience in antibody research and development, with deep expertise in antibody engineering and project management. His work spans therapeutic monoclonal antibodies, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates (ADCs). He earned his PhD from the National University of Singapore. 

Close

Kathrin Gärtner

Dr. Gärtner brings over 12 years of expertise in cancer extracellular vesicle (EV) research, with a focus on diagnostic and therapeutic applications. As co-founder and managing director, she led the operational development of Eximmium’s Munich site for four years. She earned her PhD from Ludwig-Maximilians-Universität Munich.